linjc16/ctgov huggingface dataset:
Quadratus Lumborum Block by Paraspinous Sagittal Shift Approach for Hip Surgery

Study Overview
=================
Brief Summary
-----------------
The quadratus lumborum block (QLB) was first described by Blanco. it is a compartment block procedure during which a local anesthetic is injected into the muscle plane of the quadratus lumborum (QL) muscle under ultrasound guidance Currently, QLB is divided into four types based on the injection point of the local anesthetic: lateral, anterior, posterior, and intramuscular QLB. QLB is widely used for various types of abdominal surgeries (

Detailed Description
-----------------
the investigators will evaluate the anesthetic efficacy of quadratus lumborum block by paraspinous sagittal shift approach for hip surgery by injecting 30 ml of 0. 5% bupivacaine.

Official Title
-----------------
Tthe Anaesthetic Efficacy of Quadratus Lumborum Block by Paraspinous Sagittal Shift Approach for Hip Surgery:a Case Series

Conditions
-----------------
Self Efficacy

Intervention / Treatment
-----------------
* Other: QUADRATUS LUMBORUM BLOCK


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -ASA I and II Exclusion Criteria: Contraindications for regional blocks (eg. Patient refusal Infection at the injection site, coagulopathy) Allergic reaction to drugs. opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: QLB<br>With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly. The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively. | Other: QUADRATUS LUMBORUM BLOCK<br>* QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensory and motor block level | BY PIN PRICK | immediately after the intervention/procedure/surgery |
Effect of Low Level Laser Irradiation on Muscle Performance and Recovery

Study Overview
=================
Brief Summary
-----------------
Low level laser therapy (LLLT) was shown to affect muscle performance and fatigue. The aim of this study is to investigated the effect of B-cure laser on muscle performance and recovery after intense exercise.

Official Title
-----------------
Effect of Low Level Laser Irradiation on Muscle Performance and Recovery

Conditions
-----------------
Physical Exertion

Intervention / Treatment
-----------------
* Device: B-cure laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy physical education students, ages 20-35, light or intermediate skin color Exclusion Criteria: musculoskeletal injury to hips or knees in the previous 2 months, use pharmacological agents or nutritional supplements regularly, smokers, physical limitations on completing the exercise tests -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: treatment with real laser<br>10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle. | Device: B-cure laser<br> <br> |
| Sham Comparator: sham laser<br>10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle. | Device: B-cure laser<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improvement in muscle power as indicated in 5 repetitions of flexion/extension of the knee using isokinetic dynamometer before and after laser treatment |  | 1 hour | 
| evaluation of muscle power after induction of muscle fatigue in 5 repetitions of flexion/extension of the knee using isokinetic dynamometer before and after laser treatment |  | 2 hour |
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.

Official Title
-----------------
A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia

Conditions
-----------------
Anemia

Intervention / Treatment
-----------------
* Drug: Ferric Carboxymaltose (FCM)
* Drug: Standard Medical Care (SMC) for the treatment of IDA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects ≥ 18 years of age and able to give informed consent Iron deficiency is the primary etiology of anemia Screening Visit central laboratory Hemoglobin (Hgb) ≤ 11g/dL Screening Visit ferritin ≤ 100ng/mL or ≤ 300 ng/mL when TSAT was ≤ 30% Exclusion Criteria: Previous participation in a FCM trial Known hypersensitivity reaction to FCM Requires dialysis for treatment of chronic kidney disease Current anemia not attributed to iron deficiency Received IV iron, RBC transfusion(s), or antibiotics 10 days prior and during the screening phase Anticipated need for surgery AST or ALT greater than 1.5 times the upper limit of normal Received an investigational drug within 30 days of screening Pregnant or sexually-active females who are not willing to use an effective form of birth control

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ferric Carboxymaltose (FCM)<br>750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg). | Drug: Ferric Carboxymaltose (FCM)<br> <br> |
| Active Comparator: Standard Medical Care (SMC) for the treatment of IDA<br>SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA). | Drug: Standard Medical Care (SMC) for the treatment of IDA<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC | Safety, as defined by the occurence of serious adverse events (SAE's), of FCM compared to SMC in the treatment of IDA in subjects who were not dialysis dependent | First administration of FCM, or Day 0 for SMC subjects, through end of study (Day 42) or 28 days after the last dose of study drug (FCM or SMC) whichever was longer |
UVX as an Adjuvant in the Treatment of Fungal Keratitis

Study Overview
=================
Brief Summary
-----------------
In this study, investigators want to find the effect of adjuvant collagen cross-linking in the treatment of fungal keratitis

Official Title
-----------------
UVX as an Adjuvant in the Treatment of Fungal Keratitis

Conditions
-----------------
Treatment

Intervention / Treatment
-----------------
* Drug: topical voriconazole / levofloxacin systemic itraconazole
* Radiation: CXL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fungal keratitis documented by culture or confocal scanning without any previous treatment Exclusion Criteria: Previous treatment Thinning at presentation Perforation Associated with other microbial or viral keratitis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: conventional treatment<br>In this arm, patients with documented fungal keratitis undergo conventional medical treatment. | Drug: topical voriconazole / levofloxacin systemic itraconazole<br>* starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks<br>|
| Active Comparator: conventional treatment +CXL<br>In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day | Drug: topical voriconazole / levofloxacin systemic itraconazole<br>* starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks<br>Radiation: CXL<br>* 30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration<br>* Other names: Collagen cross-linking/ UVx;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time of complete healing (days) | time to scar formation (days) | 180 days |
The SHIELD Study-silicosis

Study Overview
=================
Brief Summary
-----------------
An observational cohort study to derive biomarkers which are able to more accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery.

Detailed Description
-----------------
Background: Silicosis is a fatal lung disease caused by inhaling silica particles. Australia is currently facing an epidemic with hundreds of young workers having contracted silicosis from machining engineered stone. AIMS: To establish the SHIELD COHORT and associated SHIELD BIOBANK to drive further discovery including assessing the efficacy of whole lung lavage for accelerated silicosis, uncovering disease biomarkers, and druggable targets. PARTICIPANTS: 75 participants who are respirable crystalline silica exposed workers, (this includes n=30 with silicosis, n=15 with progressive massive fibrosis and n=30 with no pneumoconiosis). METHODS: Advanced microscopy, 'omic platforms and single cell RNA sequencing. OUTCOME: The SHIELD study builds on the knowledge gap to accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery

Official Title
-----------------
Silicosis-harnessing New Ideas to Conquer the Re-emergence of an Ancient Lung Disease

Conditions
-----------------
Silicosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All workers with a history of significant engineered stone exposure will be potentially eligible. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the SHIELD study primary outcome is to build up knowledge gap to accurately diagnose silicosis, as well as predict disease progress, assess response to treatment, hasten therapeutic discovery in 12 months. | Establish the SHIELD cohort and associated lung fluid, tissue and blood biobank from well phenotyped RCS-exposed workers identified via the screening programs. Utilise advanced microscopy, 'omic platforms and single cell RNA sequencing (scRNAseq) alongside conventional laboratory techniques, to identify and validate candidate lung and blood biomarkers associated with disease and disease progression at 12 months. To evaluate associations between baseline characteristics, biomarkers and progression of disease in the full cohort. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Silicosis, Pneumoconiosis, lung diseases
Follow-up Study for Participants Jointstem Clinical Trial

Study Overview
=================
Brief Summary
-----------------
This study is a long term follow-up study to investigate the safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Knee Osteoarthritis.

Official Title
-----------------
Open, Multicenter Follow-up Trial About Active Group of Phase IIb Clinical Trial of JOINTSTEM in Patients With Degenerative Arthritis

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Jointstem


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must consent in writing to participate in the study by signing and dating an informed consent document Patients who transplanted Jointstem on phase 2b clinical trial Exclusion Criteria: Preparing for Pregnancy or Pregnant women or lactating mothers. Patients who the principal investigator considers inappropriate for the clinical tria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Long Term Follow-up after Jointstem Transplantation<br> | Drug: Jointstem<br>* JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.<br>* Other names: autologous adipose-derived mesenchymal stem cells;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events | Incidence of adverse events from baseline to 60 months | 60 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC score | Change from baseline on WOMAC (Western Ontario and McMaster Universities Arthritis Index) score | Baseline and 12 months | 
| WOMAC 3 subscale score | Change from baseline on WOMAC 3 subscale (Pain, stiffness, and physical function) score | Baseline and 12 months | 
| X-ray | X-ray perform to measure with Kellgren-Lawrence grade | Baseline and 12 months |
Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The information collected will provide insight in to the epidemiology of antibiotic resistance in a transplant compared to a non-transplant population. Data is needed regarding the date of admission, date of bloodstream infection and location of ward/ICU so trends in the emergence of resistance and antibiotic usage can be detected.

Detailed Description
-----------------
We need to collect details on the demographics (age, sex etc), underlying conditions, transplant types and immunosuppression, in-hospital antibiotic management and clinical outcomes so that the effect of antibiotic resistance on patient outcome can be measured. We also need to collect microbiology and pathology data to determine the antibiotic susceptibility profile of the involved organisms. The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, prophylactic antimicrobials, physical exam findings, laboratory and radiographical data, empiric antimicrobial usage, microbiological data and resistance patterns, choice of antibiotic once organism identified, suspected source of infection, microbiological and clinical outcomes, laboratory results, demographic information, medications, gender, weight, ethnicity, and past medical history

Official Title
-----------------
Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients; a Comparative Study With a Non-transplant Population

Conditions
-----------------
Gram Negative Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with a positive blood culture isolate growing a gram-negative organism will be included from 1996 - 2005
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gram negative infection
Perceptions of Physiotherapy and Rehabilitation Professions

Study Overview
=================
Brief Summary
-----------------
In this study, it is aimed to determine the perspectives and satisfaction of the students of the Physiotherapy and Rehabilitation Department about the physiotherapist profession, and to compare these results according to the class periods. Our secondary aim is to determine the perspectives and satisfaction of graduate physiotherapists towards the physiotherapist profession and to compare these results according to their graduation years.

Official Title
-----------------
Perceptions of Physiotherapy and Rehabilitation Department Students and Graduated Physiotherapists About Their Professions

Conditions
-----------------
Perception, Self, Physiotherapy

Intervention / Treatment
-----------------
* Other: None intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Students in the physiotherapy and rehabilitation department or become a graduate physiotherapist Exclusion Criteria: Students or a graduate physiotherapist with serious mental illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Students<br> | Other: None intervention<br>* None intervention<br>|
| Physiotherapist<br> | Other: None intervention<br>* None intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perceptions of students/physiotherapist about the physiotherapist profession | Measuring perceptions of physiotherapist and other professions relative to each other (0-10). low scores indicate poor perception, high scores indicate good perception. [the minimum (8 point) and maximum values (80 point)], higher scores were mean a better outcome. | Baseline time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Perception, Self, Physiotherapy
Adaptation of Locomotor Activity in Patients Suffering From Hip OA - Analysis of This Adaptation as a Prognostic Criterion for Future Disease Progression

Study Overview
=================
Brief Summary
-----------------
To assess the prognostic value of a characteristic evaluation of gait in persons suffering from hip OA for subsequent indications for THR.

Conditions
-----------------
Primary Hip Osteoarthritis

Intervention / Treatment
-----------------
* Procedure: Evaluation of the balance of force platform


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women aged between 45 and 75 years Suffering from primary hip osteoarthritis defined according to ACR criteria who presented pain in the hip for at least one month in the preceding 3 months Radiological stage II, III or IV hip OA according to the Kellgren and Lawrence classification Patients able to understand simple instructions des packaging instructions, to give their written informed consent. Exclusion Criteria: Indication for THR at the time of inclusion. Pregnant or breast-feeding women Alzheimer's disease Chronic respiratory insufficiency with clinical manifestations Parkinson's disease Motor neuron disease Major musculo-skeletal disorder (other than hip OA) Severe non-stabilised diabetes Non-stabilised hypertension Hip OA inflammation flare Rapidly-destructive hip OA Radiography to evaluate structural evolution of the disease done more than 12 months previously Presence of OA in another joint, or another osteoarticular or periarticular disease of the lower limbs with, in the opinion of the patient, disability due to this other disease that is greater than the disability caused by the hip OA. Spine disease causing gait disturbance (radiculalgia, lumbar canal stenosis,… with, in the opinion of the patient, disability due to this other disease that is greater than the disability caused by the hip OA.)

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients with Primary hip osteoarthritis<br>Patients with Primary hip osteoarthritis | Procedure: Evaluation of the balance of force platform<br> <br> |
| Other: Healthy volunteer<br>Healthy volunteer | Procedure: Evaluation of the balance of force platform<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| locomotor activity |  | participants will be followed for the duration of hospital stay, an expected average of 2 weeks |